{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-051876","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.012525+00:00","generated_at":"2026-06-05T06:50:33.225090+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Verrica Q4 2023 YCANTH revenue $1.9M; net loss $24.6M vs $5.9M prior year","bullets":["Full-year 2023 YCANTH product revenue $4.7M; first commercial revenue after Q3 2023 launch.","Net loss FY 2023 $67.0M ($1.48 per share) vs $24.5M ($0.72 per share) in FY 2022; non-GAAP net loss $51.8M ($1.14 per share).","SG&A expenses surged to $47.3M for FY 2023 (FY 2022: $17.4M) driven by commercial ramp and stock compensation.","Cash and equivalents $69.5M as of Dec 31, 2023; runway into Q2 2025.","CMS issued permanent J-code for YCANTH (effective Apr 1, 2024); FDA aligned on Phase 3 design for common warts; VP-315 Phase 2 top-line data expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-051876","json":"https://secwatch.observer/filing/0001193125-24-051876.json","markdown":"https://secwatch.observer/filing/0001193125-24-051876.md","text":"https://secwatch.observer/filing/0001193125-24-051876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524051876/0001193125-24-051876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524051876/d795567d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:50:33.225090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3903b5bbb4d409cc643db00bf04ede210370c215","claim":"Verrica Pharmaceuticals Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524051876/0001193125-24-051876-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}